Kevin Williams to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Kevin Williams has written about Drug Resistance, Neoplasm.
Connection Strength
0.172
-
Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett. 2013 Aug 28; 337(1):77-89.
Score: 0.101
-
Widatalla SE, Korolkova OY, Whalen DS, Goodwin JS, Williams KP, Ochieng J, Sakwe AM. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis. 2019 08 22; 40(8):998-1009.
Score: 0.039
-
Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis. 2017 03 01; 38(3):252-260.
Score: 0.033